NASDAQ:AVDLAvadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVDL shares have increased by 4.6% and is now trading at $8.36.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avadel Pharmaceuticals.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.25. The company earned $12.24 million during the quarter, compared to analyst estimates of $10.25 million.
View Avadel Pharmaceuticals' earnings history.

8 analysts have issued 1-year price targets for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $19.00. On average, they anticipate Avadel Pharmaceuticals' stock price to reach $14.56 in the next year. This suggests a possible upside of 74.2% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals.

News coverage about AVDL stock has been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Passage Bio (ZNTL), Supernus Pharmaceuticals (SUPN), Odonate Therapeutics (ODT), Constellation Pharmaceuticals (CNST), Kiniksa Pharmaceuticals (KNSA), Akcea Therapeutics (AKCA), Arvinas (ARVN), Nabriva Therapeutics (NBRV), Arcturus Therapeutics (ARCT), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR), Akero Therapeutics (AKRO), Humanigen (HGEN), VBI Vaccines (VBIV) and Retrophin (RTRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and China Unicom (Hong Kong) (CHU).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Asymmetry Capital Management L.P. (1.42%), Calamos Advisors LLC (0.29%), Candriam Luxembourg S.C.A. (0.23%), Russell Investments Group Ltd. (0.17%), Investors Asset Management of Georgia Inc. GA ADV (0.10%) and Virtu Financial LLC (0.09%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Michael S Anderson and Sandra L Hatten.
View institutional ownership trends for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Calamos Advisors LLC, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Virtu Financial LLC, Quantitative Systematic Strategies LLC, Envestnet Asset Management Inc., and Exane Derivatives. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, and Greg J Divis.
View insider buying and selling activity for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $8.36.

Avadel Pharmaceuticals has a market capitalization of $313.08 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

The official website for Avadel Pharmaceuticals is www.avadel.com.

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]